Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
26,414 INR | -0.86% | -1.51% | +15.43% |
May. 10 | Abbott India's Net Profit Climbs in Fiscal Q4; Shares Up 3% | MT |
May. 09 | Drugmaker Abbott India posts Q4 profit rise on higher sales | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- With an expected P/E ratio at 47.47 and 43.15 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.43% | 6.8B | B- | ||
+34.35% | 705B | C+ | ||
+30.88% | 583B | B | ||
-3.49% | 364B | C+ | ||
+20.15% | 332B | B- | ||
+6.19% | 291B | C+ | ||
+15.55% | 238B | B+ | ||
-3.19% | 210B | A+ | ||
+10.43% | 209B | B- | ||
+9.21% | 169B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
- Stock Market
- Equities
- ABBOTINDIA Stock
- Ratings Abbott India Limited